scholarly journals  -Arrestin 1 Inhibits the GTPase-Activating Protein Function of ARHGAP21, Promoting Activation of RhoA following Angiotensin II Type 1A Receptor Stimulation

2010 ◽  
Vol 31 (5) ◽  
pp. 1066-1075 ◽  
Author(s):  
D. F. Anthony ◽  
Y. Y. Sin ◽  
S. Vadrevu ◽  
N. Advant ◽  
J. P. Day ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Protein Function ◽  
Gtpase Activating Protein ◽  
Receptor Stimulation

scholarly journals Possible Inhibition of Focal Cerebral Ischemia by Angiotensin II Type 2 Receptor Stimulation

Circulation ◽  
2004 ◽  
Vol 110 (7) ◽  
pp. 843-848 ◽  
Author(s):  
Masaru Iwai ◽  
Hong-Wei Liu ◽  
Rui Chen ◽  
Ayumi Ide ◽  
Shoko Okamoto ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Cerebral Ischemia ◽  
Focal Cerebral Ischemia ◽  
Receptor Stimulation

scholarly journals Site-specific monoubiquitination activates Ras by impeding GTPase-activating protein function

Small GTPases ◽  
2013 ◽  
Vol 4 (3) ◽  
pp. 186-192 ◽  
Author(s):  
G Aaron Hobbs ◽  
Harsha P Gunawardena ◽  
Rachael Baker ◽  
Xian Chen ◽  
Sharon L Campbell
Keyword(s):  
Protein Function ◽  
Gtpase Activating Protein ◽  
Site Specific

scholarly journals Angiotensin II Type 2 Receptor Stimulation

Circulation ◽  
2008 ◽  
Vol 118 (24) ◽  
pp. 2523-2532 ◽  
Author(s):  
Elena Kaschina ◽  
Aleksandra Grzesiak ◽  
Jun Li ◽  
Anna Foryst-Ludwig ◽  
Melanie Timm ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Receptor Stimulation

Direct angiotensin II type 2 receptor stimulation by compound 21 prevents vascular dementia

2015 ◽  
Vol 9 (4) ◽  
pp. 250-256 ◽  
Author(s):  
Jun Iwanami ◽  
Masaki Mogi ◽  
Kana Tsukuda ◽  
Xiao-Li Wang ◽  
Hirotomo Nakaoka ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Vascular Dementia ◽  
Receptor Stimulation ◽  
Compound 21

scholarly journals Regulation of Vascular Proteoglycan Synthesis by Angiotensin II Type 1 and Type 2 Receptors

2001 ◽  
Vol 12 (12) ◽  
pp. 2609-2615
Author(s):  
Ryoko Shimizu-Hirota ◽  
Hiroyuki Sasamura ◽  
Mizuo Mifune ◽  
Hideaki Nakaya ◽  
Mari Kuroda ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Angiotensin Ii ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Proteoglycan Synthesis ◽  
At2 Receptor ◽  
Receptor Stimulation ◽  
Epidermal Growth

ABSTRACT. Recent studies have shown that proteoglycans play an important role in the development of vascular disease and renal failure. In this study, the effects of angiotensin II (AngII) type 1 (AT1) and type 2 (AT2) receptor stimulation on glycosaminoglycan and proteoglycan core protein synthesis in vascular smooth muscle cells (VSMC) were examined. Treatment of AT1 receptor-expressing VSMC with AngII resulted in a dose-dependent and time-dependent increase (2- to 4-fold) in 3H-glucosamine/35S-sulfate incorporation, which was abolished by pretreatment with the AT1 receptor antagonist, losartan. The effects of AngII were inhibited by the epidermal growth factor receptor inhibitor, AG1478, and the mitagen-activated protein kinase kinase inhibitor, PD98059, but not the protein kinase C inhibitors, chelerythrine and staurosporine. AngII treatment also resulted in significant increases in the mRNA of the core proteins, versican, biglycan, and perlecan. The effects of AT2 receptor stimulation were examined by retroviral transfection of VSMC with the AT2 receptor. Stimulation of the AT2 receptor in these VSMC-AT2 cells resulted in a significant (1.3-fold) increase in proteoglycan synthesis, which was abolished by the AT2 receptor antagonist, PD123319, and attenuated by pretreatment with pertussis toxin. These results implicate both AT1 and AT2 receptors in the regulation of proteoglycan synthesis and suggest the involvement of epidermal growth factor receptor-dependent tyrosine kinase pathways and Gαi/o-mediated mechanisms in the effects of the two receptors.

Sign in / Sign up

Export Citation Format

Share Document